1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
G&E Herbal Biotechnology Co., Ltd.

G&E Herbal Biotechnology Co., Ltd.

TTPEX:4911
27.00
TWD
0.00
(0.00%)
1.21EPS
24.40P/E
2.04BMarket Cap
G&E Herbal Biotechnology Co., Ltd.
TPEX:4911
(Taipei Exchange)

Recent

price

27.00

P/E

ratio

24.40

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
0.47
0.38
0.45
0.63
1.11
0.79
0.5
0.32
0.03
0.26
0.41
0.36
0.94
2.64
3.62
4.49
3.03
Revenue per Share
-0.17
0.09
-0.17
-0.06
0.2
-0.17
-0.21
-0.61
-0.33
-0.34
-0.21
-0.29
0.11
1.05
1.48
2.02
1.21
Basic EPS, GAAP
-0.14
-0.16
-0.22
-1.27
-1.15
-2.23
-1.45
-0.55
-0.4
-0.38
-0.09
-0.16
1.41
1.57
1.87
0.97
0.25
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.08
- -
- -
- -
- -
- -
- -
- -
- -
0.46
0.65
- -
Dividend per Share
5.73
12.19
12.02
11.96
12.16
11.92
11.7
11.1
10.77
10.43
10.22
9.93
10.04
11.09
12.11
13.49
12.74
Book Value per Share
3.81
10.28
10.11
10.06
10.23
9.95
9.71
9.11
8.8
8.47
8.24
7.96
8.08
9.15
10.17
11.56
10.81
Tangible Book Value per Share
61
67
69
69
69
69
69
69
69
69
69
69
69
69
69
69
71
Basic Weighted Avg Shares
28
26
31
43
77
54
35
22
2
18
28
25
65
181
249
309
216
Sales/Revenue/Turnover
-53.54
-73.22
-89.43
-74.25
-4.34
-61.05
-86.63
-186.31
-1,829.73
-163.36
-54.81
-79.61
8.49
44.47
48.04
49.27
38.46
Operating Margin (%)
4
3
2
3
2
2
3
9
9
9
9
9
9
9
10
11
11
Depreciation Expense
-10
6
-12
-4
14
-12
-15
-42
-23
-23
-14
-20
7
72
102
139
86
Net Income, GAAP
- -
- -
- -
- -
17.04
- -
- -
- -
- -
- -
- -
- -
- -
20
18.17
12.12
3.37
Effective Tax Rate (%)
-36.71
22.23
-37.56
-8.89
17.88
-21.96
-42.29
-190.8
-1,028.32
-133.1
-50.66
-80.92
11.42
39.9
40.98
45.03
40
Profit Margin (%)
243
673
652
570
502
314
217
188
164
144
138
127
141
234
326
428
372
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
LT Debt
394
839
827
823
837
820
805
764
741
718
703
683
691
763
834
928
877
Total Equity
- -
- -
- -
- -
-0.33
- -
- -
- -
- -
- -
- -
- -
- -
8.81
12.14
14.91
9.06
Return on Invested Capital (%)
- -
- -
- -
- -
1.63
- -
- -
- -
- -
- -
- -
- -
- -
9.88
12.68
15.67
9.82
Return on Capital (%)
-2.62
0.93
-1.4
-0.46
1.65
-1.43
-1.8
-5.32
-3.01
-3.2
-2.01
-2.87
1.07
9.96
12.78
15.8
9.91
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
7
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
69
69
69
Market Capitalization
2,734
2,189
2,036

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
475
474
472
Cash, Cash Equivalents & STI
430
422
426
Accounts Receivable, Net
17
22
14
Inventories
25
27
26
Total Current Liabilities
47
39
101
Payables & Accruals
- -
- -
- -
ST Debt
7
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.43%
5.86%
11.34%
Free Cash Flow
-110.62%
-179.76%
-47.95%
Net Income, GAAP
98.75%
172.03%
36.38%
Sales/Revenue/Turnover
98.81%
78.44%
24.13%
Total Cash Common Dividend
- -
- -
40.59%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
55
60
62
72
249
2025
80
80
80
69
309
2026
32
34
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.32
0.4
0.45
1.48
2025
0.53
0.53
0.53
0.4
2.02
2026
0.21
0.1
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.46
2025
- -
- -
- -
- -
0.65
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
G&E Herbal Biotechnology Co., Ltd. engages in the research, development, manufacture, and commercialization of novel botanical extraction technologies and products. The company produces a diverse range of health-related products including Hepanamin capsules targeting liver-related diseases; botanical healthcare products under the G&E series; botanical anti-aging cosmetics such as facial cleansing essence, botanical extract toner, moisturizing cream, serum, essential oils, and glitter series cosmetics; botanical antila series gels; skin care products; food supplements; and adult products including lubricants. It also offers biotechnological services and is recognized for its proprietary extraction technology and standards-compliant manufacturing processes, including PIC/S GMP-certified facilities. Founded in 2002 and headquartered in Tainan City, Taiwan, G&E Herbal Biotechnology operates multiple state-of-the-art sites within Taiwan. In recent years, the company has advanced its new drug development pipeline, notably progressing SR-T100, with clinical trials reaching Phase I for injection formulations and Phase III for gel formulations. It has expanded its strategic efforts in research and commercialization of botanical new drugs and health supplements, with notable partnerships and collaborations to market its Hepanamin product. In 2025, G&E Herbal Biotechnology received the “Emerging Mid-Sized Enterprise Award” for Top 10 Growth and Top 10 Profitability, reflecting its strong financial performance and operational excellence. The company continues to focus on innovation in botanical medicine as it participates in international industry events like BIO Asia–Taiwan 2025 and the Asia Healthcare & Medical Cosmetology Expo. It emphasizes sustainable practices through adherence to Global Reporting Initiative standards and continues to pursue global market expansion with a growing portfolio of scientifically validated natural compounds and new drug candidates. The company targets healthcare markets globally with a focus on botanical drugs, dietary supplements, dermatological care, and functional cosmetics. It maintains close control over the cultivation of plant materials via contracted farmers in Taiwan and monitors quality rigorously from agricultural production through manufacturing. G&E Herbal Biotechnology is led by CEO and founder Kou-Wha Kuo and maintains a strong commitment to research ethics and innovation to deliver clinically effective botanical pharmaceutical and consumer health products to both domestic and international markets.